



STATE OF THE FIELD

- Pox-Protein Public-Private Partnership trials began in Southern Africa early 2015, testing canarypox-protein based vaccine candidates in two tracks. Key components:
 - Development track: Efficacy trial of ALVAC/protein candidate for licensure—possible start 2016/2017.
 - Research track: Small trials of altered pox-protein regimens beginning; will down-select for future proof-of-concept efficacy trial.
- Janssen, a division of Johnson & Johnson, is conducting a global development program of Ad26 vector + mosaic immunogen vaccine strategy designed to act against a range of HIV subtypes.

ADVOCATE'S CHECKLIST

- ✓ **TRACK TIMELINES**
Vaccine timelines are long; ensure possible delays are minimized
 - Ensure down-selection criteria are explicit and used.
- ✓ **FOLLOW PHARMA**
Industry involvement is essential
 - Track industry engagement and encourage Janssen and others to expand human and financial resources.
- ✓ **SUSTAIN SUPPORT**
Countries have had mixed HIV research experiences
 - Meaningfully engage in-country stakeholders to avoid misinformation and sustain support.